VivoSeq
Metabolic & Endocrine

Adult Growth Hormone Deficiency

4

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Adult Growth Hormone Deficiency is an early-stage landscape with 4 programs across 4 companies. The most active players are Ascendis Pharma A/S, Novartis, Ascendis Pharma Endocrinology Division A/S. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Ascendis Pharma A/S

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2A

Ascendis Pharma Endocrinology Division A/S

1 program

Phase 3EMD Serono logo

EMD Serono

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

CSP #2018 - Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
Recruiting·VVA Office of Research and Development·Phase 3·NCT04867317·172 enrolled
A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients With Growth Hormone Deficiency
Completed·AAscendis Pharma A/S·Phase 2·NCT01247675·37 enrolled
A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Completed·AAscendis Pharma Endocrinology Division A/S·Phase 3·NCT05171855·220 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)